
Sign up to save your podcasts
Or


The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
Released May 30, 2017.
By ReachMD4.5
22 ratings
The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
Released May 30, 2017.

39 Listeners

10 Listeners

59 Listeners

1,150 Listeners

195 Listeners

45 Listeners

7 Listeners